News
ADCT
4.440
-7.11%
-0.340
Weekly Report: what happened at ADCT last week (0415-0419)?
Weekly Report · 3d ago
ADC Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 04/15 12:02
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $9 Price Target
Benzinga · 04/15 11:51
Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress
TipRanks · 04/15 10:16
Weekly Report: what happened at ADCT last week (0408-0412)?
Weekly Report · 04/15 09:03
Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
TipRanks · 04/11 15:30
Adc Therapeutics Sa: Current report
Press release · 04/10 00:05
ADC Therapeutics Showcases Cancer Treatment Innovations
TipRanks · 04/09 20:23
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/09 03:00
Weekly Report: what happened at ADCT last week (0401-0405)?
Weekly Report · 04/08 09:03
Guggenheim Reiterates Buy on ADC Therapeutics
Benzinga · 04/05 13:55
Health Care Sector Update for 04/04/2024: FNA, SLP, ADCT, ALUR
NASDAQ · 04/04 20:03
Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), TFF Pharmaceuticals (TFFP)
TipRanks · 04/04 17:20
ADC Therapeutics gains after data for lymphoma therapy
ADC Therapeutics gains after data for lymphoma therapy. Swiss biotech announced data from a Phase 1b trial. The company says drug combo indicated no toxicities or cytokine release syndrome in lymphoma patients. The drug is a late-line option for patients with lymphoma.
Seeking Alpha · 04/04 17:11
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Benzinga · 04/04 11:05
ADC THERAPEUTICS SA - IN DOSE ESCALATION PORTION (PART 1) OF LOTIS-7, NO DOSE-LIMITING TOXICITIES WERE OBSERVED ACROSS ALL PATIENTS
Reuters · 04/04 11:00
Weekly Report: what happened at ADCT last week (0325-0329)?
Weekly Report · 04/01 09:03
ADC Therapeutics Price Target Announced at $11.00/Share by Guggenheim
Dow Jones · 03/28 10:56
ADC Therapeutics Initiated at Buy by Guggenheim
Dow Jones · 03/28 10:56
Guggenheim Initiates Coverage On ADC Therapeutics with Buy Rating, Announces Price Target of $11
Benzinga · 03/28 10:45
More
Webull provides a variety of real-time ADCT stock news. You can receive the latest news about Adc Therapeutics Sa through multiple platforms. This information may help you make smarter investment decisions.
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.